Navigation Links
Access and Somanta Announce Data to be Presented on Angiolix at,ASCO Oncology Conference

Pre-clinical Data Suggests Angiolix Can Inhibit Breast Cancer Growth By 75%

DALLAS and IRVINE, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (Bulletin Board: ACCP) and Somanta Pharmaceuticals, Inc. (Bulletin Board: SMPM) announced today that a scientific abstract outlining new preclinical efficacy data for Somanta's Angiolix has been selected for publication in the Proceedings of the 43rd American Society of Clinical Oncology (ASCO) Annual Meeting to be held in Chicago, IL, June 1-5, 2007. The data, in a study conducted using mouse models, shows that Angiolix has been able to achieve more than 75% growth inhibition of human breast cancer growing as xenografts in mouse.

ASCO's annual meeting is the world's premier oncology conference providing information on the latest developments in cancer treatment. As previously announced Access and Somanta have signed a definitive merger agreement for Access to acquire Somanta as a step in the creation of a combined company with a broad cancer-focused portfolio in which Angiolix will be a major program.

Angiolix is a humanized monoclonal antibody that recognizes a migrating adhesion molecule called Lactadherin. Somanta's recent data suggests that tumor cells express Lactadherin which is a factor in the growth of tumor vasculature. Several existing or potential anti-cancer drugs (such as Avastin) seek to block tumor vascularization by blocking a signaling protein know as vascular endothelial growth factor (VEGF). The binding of Angiolix to Lactadherin is thought to cause a VEGF-independent integrin receptor signaling cascade that blocks vascular endothelial cell proliferation. Due to its ability to neutralize Lactadherin-integrin receptor binding, Angiolix may be able to specifically target breast cancer cells and thereby cause tumor suppression by blocking the growth of tumor vasculature.

Dr. Agamemnon Epenetos, CEO of Som
'"/>




Page: 1 2 3

Related medicine technology :

1. PromegaExpress Expands Easy Access to Products with New Cabinet
2. Access Pharmaceuticals Announces Poster Presentations on ProLindac at the American Association for Cancer Research 2007 Annual Meeting
3. Somanta Announces the Presentation of Alchemix Data at The American Association for Cancer Research Annual Meeting
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:12/24/2014)... Dec. 23, 2014  The American Diabetes Association ... target for people with diabetes and that all ... doses of statins, in keeping with recent changes ... the American College of Cardiology (ACC) and American ... the most recent changes to the Association,s annual ...
(Date:12/22/2014)... JUNCTION, N.J. , Dec. 22, 2014 /PRNewswire/ ... company marketing its CytoSorb® blood purification technology to ... surgery patients in 28 countries worldwide, today announced ... Russo , MD, FACS, as its Senior Vice ... Dr. Di Russo ...
(Date:12/22/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/hmlfbq/investment ) ... Analysis of the US Medical Device Sector " ... http://photos.prnewswire.com/prnh/20130307/600769 This analysis ... identifies the key trends and rationale for undertaking ... and acquisitions. The study will be ...
Breaking Medicine Technology:New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5Investment Analysis of the US Medical Device Sector 2
... a.m. EDT-, MONTVALE, N.J., Oct. 15 ... top-line data from the,multi-center, randomized, double-blind, placebo-controlled Phase ... channel modulator, in Alzheimer,s,disease. The trial enrolled 183 ... 40 centers in the United States and included ...
... Fla., Oct. 13 Acutely ill, hospitalized,patients ... taking INVEGA(TM) (paliperidone) Extended-Release Tablets as compared,to ... with INVEGA as early as five days ... the two-week study period, according to preliminary ...
Cached Medicine Technology:Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease 2Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease 3Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease 4INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients 2INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients 3INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients 4INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients 5INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients 6INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients 7
(Date:12/25/2014)... (PRWEB) December 25, 2014 BambooFlooringChina.com sells ... high quality bamboo flooring. Today, the company announces ... in many styles and colors. , BambooFlooringChina.com is the ... CEO, the promotion is valid until Jan. 20, 2015. ... strips and woven with a natural thread. All the ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 When head lice ... themselves in a frenzy to get rid of it while ... families in Coral Gables now have the solution right in ... salon clinic location, Lice Troopers provides full spectrum head lice ... Coral Gable area, including Sunset, Key Biscayne, Brickell, Coconut Grove, ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, ... illnesses can receive effective, less expensive care from a clinic ... a team of dedicated health care professionals, a new study ... and need either hospitalization or a trip to the emergency ... clinic at the University of Texas in Houston versus usual ...
(Date:12/25/2014)... 2014 (HealthDay News) -- Overeating is common during the holidays, ... moderation, an expert says. "Don,t arrive at a party ... you know you,ll be attending a party, but deprivation leads ... dietitian at Northern Westchester Hospital in Mount Kisco, N.Y., said ... healthy during the day and even to have a snack ...
(Date:12/25/2014)... Dennis Thompson HealthDay ... Researchers could be closing in on a "fountain of youth" ... the health of older adults, a new study suggests. ... given a drug that targets a genetic signaling pathway linked ... Novartis report. The experimental medication, a version ...
Breaking Medicine News(10 mins):Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3
... for about half of all visits to psychotherapists, and ... with couples.// The therapist helps the couple work on ... perpetuate conflict, explains the March 2007 issue of the ... make little use of psychiatric diagnosis, but they do ...
... of breastfeeding outweigh the risks of virus transmission from HIV-positive ... African nations.// ,A study in Zambia showed ... breast milk ¯ beyond a set time period of ... The study was a collaboration between US universities and University ...
... shows that a form of vitamin A used to treat ... small molecules called microRNAs (miRNAs) in the// leukemic cells. ... miRNAs inhibit the action of two genes important for cancer ... ,The drug is called all-trans-retinoic acid (ATRA) and it ...
... of bioactive compounds in the blood and boost antioxidant ... start// to rival the juice for boosting health. ... rise, particularly in the UK where sales have rocketed ... the antioxidant-rich fruit that has commonly been linked to ...
... in Porirua is not linked to a cluster of cases ... have been treated for typhoid in Porirua and those cases ... of health, regional public health, Wellington, said last night. ... which was being treated very seriously. ,Two of ...
... According to a study published on bmj.com, the second born ... This study also states that there is no big// difference ... second twin born at or after the complete term of ... shortly after birth. ,Many studies have talked about ...
Cached Medicine News:Health News:Breastfeeding Benefits may Outweigh HIV Risk 2Health News:Leukemia Drug Turns Mini-Molecules Up, Cancer Genes Down 2Health News:Science Builds Behind Pomegranate Extracts for Health 2
Clinac Platinum Plus accelerators offer all the high performance features of the EX series and come with the latest high-precision dose sculpting technology for advanced tumor control....
... EX accelerators are true ... Varian multileaf collimation and ... which enable you to ... computer-driven IMRT treatments, as ...
The Clinac 2300 C/D family of accelerators are reliable, easy-to-use, flexible and cost-effective systems....
... reliable system. Varian accelerators offers highest ... fastest beam-on times to full stability ... milliseconds, pulse-to-pulse beam control for dynamic ... of multileaf collimator (MLC) products that ...
Medicine Products: